SCHEMBL1443989

SCHEMBL1443989

OC(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.61
USP2 O75604 1/20 0.61
CYP19A1 P11511 7/20 0.57
KCNN4 O15554 4/20 0.55
KCNE1 P15382 1/20 0.46
KCNQ1 P51787 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 2/20 0.44
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KIF11 P52732 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL813148 1.00 RAB9A (0.61) RAB9AUSP2CYP19A1KCNN4KCNE1
Hydrochloric Acid SCHEMBL19583319 0.93 USP2 (0.55) RAB9AUSP2CYP19A1KCNN4KCNE1
SCHEMBL12833774 0.89 RAB9A (0.73) RAB9AUSP2CYP19A1KCNN4SMN1; SMN2
SCHEMBL7442397 0.88 USP2 (0.85) RAB9AUSP2CYP19A1KCNN4CYP3A4
SCHEMBL9050608 0.87 CYP19A1 (0.54) RAB9AUSP2CYP19A1KCNN4ALDH1A1
SCHEMBL10631898 0.84 CYP19A1 (0.86) RAB9AUSP2CYP19A1CYP3A4
Triphenylmethanol SCHEMBL456603 0.84 CYP19A1 (0.50) CYP19A1KCNN4ALDH1A1KMT2ACYP3A4
Triphenylmethanol SCHEMBL1332873 0.84 CYP19A1 (0.50) CYP19A1KCNN4ALDH1A1KMT2ACYP3A4
Triphenylmethanol SCHEMBL700 0.84 CYP19A1 (0.50) CYP19A1KCNN4ALDH1A1KMT2ACYP3A4
SCHEMBL30293723 0.83 KCNN4 (0.58) RAB9AUSP2CYP19A1KCNN4KCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286389-B2 Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof Shenzhen Jingtai Technology Co., Ltd (CN) 2025-04-29 US disclosed
US-20220033347-A1 CRYSTALLINE FORM A OF 2, 2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Jingtai Technology Co., Ltd (CN) 2022-02-03 US disclosed
WO-2011034860-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS ICAGEN, INC. (US) 2011-03-24 WO disclosed
US-20100056637-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS ICAGEN, INC. (US) 2010-03-04 US disclosed
US-20090036538-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS ICAGEN, INC. (US) 2009-02-05 US disclosed
EP-1968563-A2 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS Icagen, Inc. (US) 2008-09-17 EP disclosed
EP-1158971-B1 GARDOS CHANNEL ANTAGONISTS ICAGEN INC (US) 2007-08-22 EP disclosed
US-20070185209-A1 Treatment methods using triaryl methane compounds ICAGEN, INC. (US) 2007-08-09 US disclosed
WO-2007075849-A2 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS ICAGEN, INC. (US) 2007-07-05 WO disclosed
EP-1158971-A4 GARDOS CHANNEL ANTAGONISTS ICAGEN INC (US) 2003-04-16 EP disclosed
EP-1158971-A1 GARDOS CHANNEL ANTAGONISTS Icagen, Inc. (US) 2001-12-05 EP disclosed
US-6288122-B1 A TRIPHENYL ACETAMIDE ICAGEN, INC. 2001-09-11 US disclosed
WO-2000050026-A1 GARDOS CHANNEL ANTAGONISTS ICAGEN, INC. (US) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185209-A1 Treatment methods using triaryl methane compounds KCNH3, KCNH2, KCNJ2 RAB9A 4151/4885USP2 2951/4885CYP19A1 2583/4885
US-20090036538-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS KCNH3, KCNH2, KCNJ2 RAB9A 4151/4885USP2 2951/4885CYP19A1 2583/4885
US-12286389-B2 Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof WEE2, WEE1, WASF2 RAB9A 3017/4885USP2 1535/4885CYP19A1 488/4885
US-20220033347-A1 CRYSTALLINE FORM A OF 2, 2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF WEE2, WEE1, WASF2 RAB9A 3017/4885USP2 1535/4885CYP19A1 488/4885
US-20100056637-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS LTC4S, LTB4R2, CYSLTR2 RAB9A 3445/4885USP2 1539/4885CYP19A1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.